Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 10/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | PAK3 | O75914 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487848 | 0.89 | EGFR (0.37) | NTRK1PIK3C3 | |
| SCHEMBL17488065 | 0.87 | MCHR1 (0.35) | IGF1R | |
| SCHEMBL17488328 | 0.87 | MCHR1 (0.35) | — | |
| SCHEMBL17488324 | 0.85 | IGF1R (0.44) | IGF1RNTRK1PIK3C3PAK3PAK1 | |
| SCHEMBL18965789 | 0.80 | ATP1A1 (0.35) | — | |
| SCHEMBL17488326 | 0.79 | MCHR1 (0.43) | NTRK1PIK3C3PAK3 | |
| SCHEMBL17488048 | 0.79 | MCHR1 (0.38) | — | |
| SCHEMBL18965825 | 0.78 | JAK2 (0.35) | NTRK1PIK3C3 | |
| SCHEMBL18960462 | 0.78 | ATP1A1 (0.40) | — | |
| SCHEMBL17488243 | 0.74 | PLK4 (0.42) | IGF1RNTRK1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | IGF1R 1291/4885NTRK1 1236/4885PIK3C3 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.